Artera vs Ibex Medical Analytics

Ibex describes Prostate Detect as detecting prostate cancer on biopsy slides. The FDA cleared it in January 2025 as K241232, listed as Galen Second Read. Ibex sells to laboratories and health systems on enterprise contracts and offers an open API for scanners and LIS. Urology Times, citing FDA summary figures, reports a 99.6% positive predictive value for heatmap accuracy and says pathologists without AI missed 13% of the cancers the AI found. By the vendor's account its breast and gastric tools are research use only in the US.

Artera works after the diagnosis. ArteraAI Prostate holds a De Novo, DEN240068, from July 2025 for 10-year risk of distant metastasis and prostate cancer-specific mortality in males 55 or older, and the commercial test is ordered from Artera's CLIA lab. Clinical Cancer Research compared the Decipher genomic classifier with Artera's MMAI patient by patient in 2026, with an Artera-affiliated author. Pathology labs and health systems buy Ibex for the read, while clinicians treating a diagnosed prostate cancer order Artera.